MX2018014160A - Procesos para preparar oligomeros de morfolino fosforodiamidato. - Google Patents

Procesos para preparar oligomeros de morfolino fosforodiamidato.

Info

Publication number
MX2018014160A
MX2018014160A MX2018014160A MX2018014160A MX2018014160A MX 2018014160 A MX2018014160 A MX 2018014160A MX 2018014160 A MX2018014160 A MX 2018014160A MX 2018014160 A MX2018014160 A MX 2018014160A MX 2018014160 A MX2018014160 A MX 2018014160A
Authority
MX
Mexico
Prior art keywords
processes
morpholino oligomers
phosphorodiamidate morpholino
preparing
oligomer
Prior art date
Application number
MX2018014160A
Other languages
English (en)
Spanish (es)
Inventor
Cai Bao
Martini Mitchell
Thomas Katie
Shimabuku Ross
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of MX2018014160A publication Critical patent/MX2018014160A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2018014160A 2016-06-30 2017-06-30 Procesos para preparar oligomeros de morfolino fosforodiamidato. MX2018014160A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662357134P 2016-06-30 2016-06-30
US201662357153P 2016-06-30 2016-06-30
US201762508256P 2017-05-18 2017-05-18
PCT/US2017/040311 WO2017205879A2 (fr) 2016-05-24 2017-06-30 Procédés de préparation d'oligomères morpholino de phosphorodiamidate

Publications (1)

Publication Number Publication Date
MX2018014160A true MX2018014160A (es) 2019-04-01

Family

ID=64425889

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014160A MX2018014160A (es) 2016-06-30 2017-06-30 Procesos para preparar oligomeros de morfolino fosforodiamidato.

Country Status (10)

Country Link
EP (1) EP3463389A4 (fr)
JP (1) JP7022079B2 (fr)
KR (1) KR102523522B1 (fr)
CN (1) CN109152792B (fr)
AU (1) AU2017270598B2 (fr)
CA (1) CA3024153A1 (fr)
CO (1) CO2018013831A2 (fr)
MX (1) MX2018014160A (fr)
SG (1) SG11201809502YA (fr)
WO (1) WO2017205879A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
MA45183A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
CN109152775B (zh) * 2016-06-30 2022-04-26 萨勒普塔医疗公司 制备磷酸二酰胺吗啉代寡聚物的方法
EP4230196A1 (fr) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Composés à utiliser dans le traitement des dystrophinopathies
KR20240105985A (ko) 2022-12-29 2024-07-08 최해용 스마트폰 용 프로젝터

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3022967B2 (ja) 1985-03-15 2000-03-21 アンチバイラルズ インコーポレイテッド 立体規則性ポリヌクレオチド結合ポリマー
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
EP0433345B1 (fr) 1988-09-01 1994-04-20 Forskningscenter Riso Procede de synthese de peptides et support solide de realisation dudit procede
AU694157B2 (en) * 1993-12-29 1998-07-16 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine adenosine antagonists
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8076476B2 (en) * 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
US8299206B2 (en) * 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
MX2010004955A (es) 2007-11-15 2010-06-30 Avi Biopharma Inc Metodo de sintesis de oligomeros de morfolina.
US9050373B2 (en) * 2010-05-13 2015-06-09 The Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
KR20200133284A (ko) * 2010-05-28 2020-11-26 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
TWI541024B (zh) * 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
RS55610B1 (sr) 2010-09-30 2017-06-30 Nippon Shinyaku Co Ltd Derivat morfolino nukleinske kiseline
WO2012150960A1 (fr) * 2011-05-05 2012-11-08 Avi Biopharma, Inc. Conjugués peptides/oligonucléotides
ES2727481T3 (es) * 2011-11-30 2019-10-16 Sarepta Therapeutics Inc Inclusión inducida de exón en atrofia muscular espinal
RS58529B1 (sr) * 2013-03-14 2019-04-30 Sarepta Therapeutics Inc Sastavi koji preskaču egzon za tretiranje mišićne distrofije
NZ731587A (en) * 2013-03-14 2021-07-30 Sarepta Therapeutics Inc Exon skipping compositions for treating muscular dystrophy
WO2014189142A1 (fr) * 2013-05-24 2014-11-27 味の素株式会社 Procédé de fabrication de morpholino-oligonucléotide
TWI737736B (zh) * 2016-05-24 2021-09-01 美商薩羅塔治療公司 製備磷醯二胺嗎啉代寡聚物之方法
MA49775A (fr) * 2016-05-24 2020-06-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
TW201811807A (zh) * 2016-06-30 2018-04-01 美商薩羅塔治療公司 用於肌肉萎縮症之外顯子跳躍寡聚物
CN109152775B (zh) * 2016-06-30 2022-04-26 萨勒普塔医疗公司 制备磷酸二酰胺吗啉代寡聚物的方法

Also Published As

Publication number Publication date
EP3463389A2 (fr) 2019-04-10
KR102523522B1 (ko) 2023-04-20
CO2018013831A2 (es) 2018-12-28
CA3024153A1 (fr) 2017-11-30
CN109152792A (zh) 2019-01-04
WO2017205879A2 (fr) 2017-11-30
JP7022079B2 (ja) 2022-02-17
EP3463389A4 (fr) 2020-02-19
AU2017270598A1 (en) 2019-01-17
WO2017205879A3 (fr) 2018-01-18
KR20190020674A (ko) 2019-03-04
SG11201809502YA (en) 2018-12-28
AU2017270598B2 (en) 2022-12-01
CN109152792B (zh) 2021-09-14
JP2019518748A (ja) 2019-07-04

Similar Documents

Publication Publication Date Title
SA518400462B1 (ar) عمليات لتحضير أوليجومرات فوسفوروداي أميدات مورفولينو
SA518400500B1 (ar) عمليات لتحضير أوليجومرات
MX390906B (es) Procesos para preparar oligómeros de morfolino fosforodiamidato.
SA518400463B1 (ar) عمليات لتحضير أوليجومرات فوسفوروداي أميدات مورفولينو
MX2018014160A (es) Procesos para preparar oligomeros de morfolino fosforodiamidato.
MX2016012419A (es) Formas solidas de ibrutinib y procesos para la produccion de las mismas.
MX385037B (es) Preparacion de 14-metil-16-oxabiciclo[10.3.1]pentadecenos de 3-metil-1,5- ciclopentadecanediona.
SA518391776B1 (ar) تخليق انتقائي مزدوج التجاسم لمشتقات الفوسفات
CY1120380T1 (el) Διαδικασια για την παρασκευη παραγωγων 4,6-δις(αρυλοξυ)πυριμιδινης
WO2016207914A3 (fr) Procédé de préparation d'oltipraz
MX2022001549A (es) Nuevas sintesis telescopicas de 2-metoximetil-p-fenilendiamina.
NZ720106A (en) A process for the preparation of regadenoson
TW201613953A (en) Process for the preparation of cyclic depsipeptides
MX2018009847A (es) Metodo para preparar derivado de polietilenglicol-dialdehido.
MX2020007646A (es) Procesos para la sintesis de sulfentrazona.
MX381604B (es) Proceso para preparar de temozolomida y un intermediario.
WO2016076573A3 (fr) Procédé de préparation de blonanserin et son intermédiaire
EA201791098A1 (ru) Способ синтеза производных бензазепина
GB201722027D0 (en) Sodium formate synthesis intermediate high purity carbon monoxide production plant
MX2020003543A (es) Metodo de produccion de un compuesto intermediario para sintetizar un medicamento.
IN2014CH01142A (fr)
MX365384B (es) Metodo de sintesis de derivados de 9-alilcamptotecina.
IN2013MU04068A (fr)
GB201722030D0 (en) Thiourea dioxide synthesis intermediate high purity hydrogen peroxide production plant
MX2017016161A (es) Nuevo proceso de sintesis de diazoxida.